

Synthesis and Biological Evaluation of Analogues of Cryptolepine, an Alkaloid Isolated from the Suriname Rainforest¹

Shu-Wei Yang,[†] Maged Abdel-Kader,[†] Stan Malone,[‡] Marga C. M. Werkhoven,[§] Jan H. Wisse,[⊥] Isia Bursuker,^{||} Kim Neddermann,^{||} Craig Fairchild,[▽] Carmen Raventos-Suarez,[▽] Ana T. Menendez,[▽] Kate Lane,[▽] and David G. I. Kingston^{*,†}

Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0212, Conservation International Suriname, Burenstrasse 7, Paramaribo, Suriname, The National Herbarium of Suriname, P.O. Box 9212, Paramaribo, Suriname, Bedrijf Geneesmiddelen Voorziening Suriname, Commissaris Roblesweg 156, Geysersluit, Suriname, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492-7660, and Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 05843

Received February 1, 1999

Bioassay-guided fractionation of an extract of a mixture of *Microphilis guyanensis* and *Genipa americana* collected in the rainforest of Suriname yielded the known alkaloid cryptolepine (**2**) as the major active compound in a yeast bioassay for potential DNA-damaging agents; the same compound was later reisolated from *M. guyanensis*. The structure of cryptolepine was identified unambiguously by spectral data and by its total synthesis. Several cryptolepine derivatives (**3–29**, **32–41**) were synthesized based on modifications of the C-2, N-5, N-10, and C-11 positions. Two cryptolepine dimers (**30**, **31**) were also prepared. The structure modifications did not result in compounds with a higher potency than the parent compound cryptolepine in the yeast assay system, although some derivatives did show significant activity. Selected compounds (**6**, **7**, **17**, **22**, **23**, **26**, and **27**) were also tested for cytotoxicity in mammalian cell culture, and two compounds showed significant cytotoxic activity.

In continuation of our search for anticancer and other bioactive agents from the Suriname rainforest,² an extract of a mixture of *Microphilis guyanensis* (A. DC) Pierre (Sapotaceae) and *Genipa americana* L. (Rubiaceae) collected on an ethnobotanical basis near Asindopo village in the rain forest of Suriname³ was found to show strong but nonselective activity in a yeast bioassay utilizing mutants 1138, 1140, and 1353 of the yeast *Saccharomyces cerevisiae*.⁴ In this assay system, general DNA-damaging agents and antifungal agents show activity against all three strains.² This extract was thus selected for further investigation.

Results and Discussion

Isolation Studies. Bioassay-guided fractionation of the extract was carried out using a combination of column chromatography with Sephadex LH-20 and MCI gel to yield compound **1** as the major active component. Once the salt nature of **1** became clear it was obtained more efficiently by an acid–base partition using methods described in the literature,⁵ followed by further purification by chromatography on LH-20.

The structure of compound **1** was assigned as cryptolepine hydrochloride by NMR techniques and HRFABMS, and its anion was determined as chloride using negative-ion FABMS ($Cl^- = m/z$ 35, 37). The ¹H and ¹³C NMR resonances for **1** were assigned unambiguously by spectral data including ¹H–¹H COSY, HMBC, HMQC, and ROESY spectra, and are listed in the Experimental Section; most NMR data are reported for the free base cryptolepine (**2**)

instead of its hydrochloride **1**. The free base form of compound **1** was identified as cryptolepine (**2**) by comparison of its ¹H NMR data with literature data. Compound **1** was active in the 1138, 1140, and 1353 yeast strains, with IC₁₂ values of 0.6 µg/mL in each strain. It was also cytotoxic to the M109 cell line, with an IC₅₀ of <1 µg/mL.

Following the completion of this work an extract of *M. guyanensis* (A. DC) (Sapotaceae) was reinvestigated and found to contain cryptolepine, thus implicating this plant as the source of cryptolepine in the mixed extract.

Cryptolepine has previously been isolated from *Cryptolepis triangularis* N. E. Br.,⁶ *Cryptolepis sanguinolenta* from Africa,⁷ and *Sida* sp. (Malvaceae) from Sri Lanka.⁸ Most recently it has been isolated as the antihyperglycemic principle of *C. sanguinolenta*,⁹ and the introduction to this paper provides a useful bibliography of previous work on cryptolepine, including its antimicrobial, antibacterial, antiinflammatory, antihypertensive, antipyretic, antimuscarinic, antithrombotic, noradrenergic receptor antagonistic, vasodilative, antimalarial, and antihyperglycemic biological activities. Cryptolepine belongs to the indoloquinoline alkaloid family, a relatively rare group of alkaloids in Nature, and interestingly its total synthesis was accomplished before its isolation from nature.¹⁰ Because of its various interesting biological activities, several synthetic pathways related to cryptolepine and its derivatives have been established.¹¹ Other examples of natural indoloquinolines include quindoline, hydroxycryptolepine, cryptolepine, and cryptolepine,¹² cryptolepine,¹³ neocryptolepine,¹⁴ and isocryptolepine.¹⁵

Synthetic Studies. Because of the promising biological activity of cryptolepine in both our yeast assays and in the M109 cytotoxicity assay, we decided to carry out a limited study of the structure–activity relationships of this class of compound. A similar study was also carried out by Bierer and co-workers independently of this work.¹⁶ The compounds prepared by Bierer et al. are, however, for the most

* To whom enquiries should be addressed. Tel.: (540) 231-6570. Fax: (540) 231-7702. E-mail: dkingston@vt.edu.

[†] Virginia Polytechnic Institute and State University.


[‡] Conservation International, Suriname.

[§] National Herbarium of Suriname.


[⊥] Bedrijf Geneesmiddelen Voorziening Suriname.

^{||} Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford.


[▽] Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton.




- 1 R = CH₃; X = Cl
 5 R = CH₃; X = I
 6 R = CH₃; X = Tf
 7 R = CH₂CH₃; X = I
 8 R = CH₂CH₂CH₃; X = I
 9 R = CH₂CH₂CH₂CH₃; X = Br




- 3 R = CO₂H
 23 R = CO₂CH₃
 24 R = CH₂OH
 25 R = CHO
 26 R = CH₃
 28 R = COCl
 29 R = COOCH₂CH₂OH




27



2 Cryptolepine






- 4 R = H
 10 R = CH₃
 11 R = CH₂CH₃
 12 R = CH₂CH₂CH₃
 13 R = CH₂CH₂CH₂CH₃
 14 R = CH₂CH=CH₃
 15 R = CH₂C₆H₅
 16 R = COCH₃




- 17 R = CH₃; X = Tf
 18 R = CH₂CH₃; X = Tf
 19 R = CH₂CH₂CH₃; X = Tf
 20 R = CH₂CH₂CH₂CH₃; X = Tf
 21 R = CH₂CH=CH₃; X = Tf
 22 R = COCH₃; X = Cl

Scheme 1




4




- 5 R = CH₃; X = I
 6 R = CH₃; X = Tf
 7 R = CH₂CH₃; X = I
 8 R = CH₂CH₂CH₃; X = I
 9 R = CH₂CH₂CH₂CH₃; X = Br


Scheme 2



4



- 10 R = CH₃
 11 R = CH₂CH₃
 12 R = CH₂CH₂CH₃
 13 R = CH₂CH₂CH₂CH₃
 14 R = Allyl
 15 R = Benzyl



- 17 R = CH₃
 18 R = CH₂CH₃
 19 R = CH₂CH₂CH₃
 20 R = CH₂CH₂CH₂CH₃
 21 R = Allyl

part different than those described in this work, and the bioassays used are also different.


The total synthesis of 5-*N*-methylquindolinium salts was achieved by the methods described in the literature (Scheme 1).^{9–11} Thus quindoline 11-carboxylic acid (**3**) was prepared by condensation of isatin and indoxyl-1,3-diacetate in aqueous KOH under argon,^{10,11} and decarboxylated by heating at 300 °C to yield quindoline (**4**) in sublimed form. 5-*N*-Methylation of **4** could then be carried out in two ways: treatment of quindoline mixed with iodomethane in methanol in a tightly closed vial at 110 °C for 4 h gave the iodide salt (**5**),¹⁰ while treatment with methyl triflate in toluene at room temperature⁹ gave the triflate salt (**6**). The 5-*N*-ethyl-, 5-*N*-propyl-, and 5-*N*-butylquindolines (**7**, **8**, and **9**, respectively) were prepared by alkylation with iodoethane, propyl iodide, and butyl bromide, respectively, at high temperatures in different solvents. Attempted alkylation using isopropyl bromide and 1,4-dibromobutane failed to produce quaternary salts.

Modification at the N-10 position was achieved by treating quindoline **4** with base (BaO and KOH), followed by treatment with the selected alkylating agent (methyl, ethyl, or propyl iodide, butyl bromide, allyl bromide, or benzyl bromide), as described for the synthesis of 10-*N*-methylquindoline (**10**),⁹ to yield compounds **10–15** (Scheme 2). 10-*N*-Acetylquindoline (**16**) was obtained from treatment of quindoline (**4**) with acetic anhydride in pyridine. Since methyl substitution on N-5 is the most effective substitution for biological activity in our assays, all of the 10-*N*-alkyl quindolines obtained were converted to their 5-*N*-methyl derivatives (**17–21**) by treatment with methyl triflate. 5-*N*-Methyl-10-*N*-acetylquindolinium chloride (**22**) was prepared by acetylation of **1** in the usual way.

For modifications at the 11 position (Scheme 3), quindoline 11-carboxylic acid (**3**) was methylated to its methyl ester **23** with diazomethane, and **23** was reduced under moderate conditions to the alcohol **24** with lithium aluminum hydride (LAH). The use of excess LAH and a longer duration of reflux gave 11-methylquindoline (**26**) as the only reduced product, while oxidation of **24** with pyridinium dichromate (PDC) gave aldehyde **25**. The presence of the 11-CH₂OH and 10-NH groups of compound **24** allowed the formation of cyclic carbamate **27** by the use of 1,1'-carbonyl diimidazole (CDI) and imidazole in CH₂Cl₂.

Further transformations of these 11-substituted compounds yielded additional products. Thus two dimers were

Scheme 3




prepared through acid chloride **28**; the dimeric diester **30** and the cyclic dimer **31**. Diester **30** was prepared from mono-ester **29**, which itself was formed by treatment of acid chloride **28** with ethylene glycol. A second acylation of **29** with **3** under more vigorous conditions gave **30**. The dimer **31** was made by self-condensation between two acid chlorides (**28**), as previously described.^{11a} Finally in this group an aminopropanediol side chain was attached at the C-11 position of **25** through reductive coupling of 2-amino-2-methyl-1,3-propanediol to give compound **32**; similar derivatives of polycyclic aromatic hydrocarbons have shown improved anticancer activity.¹⁷

2-Bromoquindoline-11-carboxylic acid (**33**) was prepared through condensation of 5-bromoisatin and indoxyl-1,3-diacetate. The decarboxylation of **33** at 300 °C led to both decarboxylation and debromination, to generate quindoline (**4**) as the major product. 11-Carboxylquindoline was found to be the major product when the temperature was controlled at 270–280 °C for 1 h, indicating that debromination occurs before decarboxylation. 2-Bromoquindoline could thus not be obtained in acceptable yield by this route. Some 2-bromo-11-substituted quindolines were prepared, including the methyl ester **34**, the acid halide **35**, and the amide **36**. Bioassay of compound **34** gave an IC_{12} value of 100 $\mu\text{g/mL}$ in the 1138 strain, which was worse than that of compound **23** lacking the bromine substitution. This indicated that the 2-bromo substitution decreases activity, and the preparation of other derivatives of 2-bromo-substituted quindolines was not pursued.

A final modification was the substitution of an oxygen atom for the nitrogen atom at the 10-position. The ring system of the target compound **40** has been synthesized previously.¹⁸ We modified the route to improve the yield, shown in Scheme 4; a similar strategy has been applied to the synthesis of quindoline (**4**) from quinolone.^{11c} Intermediates **37** and **38**^{18c} and target compound **40** were synthesized. Finally, 5-*N*-methylation was achieved by refluxing a mixture of compound **40**, MeI and MeOH in the presence of NaOMe. Compound **39**, in which the 11-chloro substituent is converted to an 11-iodo substituent, was obtained as the major product when 5-*N*-methylation of compound **38** was attempted under the same conditions used for

Scheme 4



compound **41**. Presumably iodide ion generated from reaction of MeI with methoxide acts as a nucleophile to displace the 11-chloro substituent, and *N*-methylation is inhibited by the electron-withdrawing nature of the halo substituent.


Biological Studies. The bioassay results are shown in Table 1; most of the compounds were tested only in the 1138 yeast strain, so these results will be discussed first.

The initial conclusion is that methylation at the 5-*N*-position is critical for activity. Thus quindoline (**4**) has an IC_{12} of 150 $\mu\text{g/mL}$, but its 5-*N*-methyl derivative **1** has an IC_{12} of 0.6 $\mu\text{g/mL}$. Replacement of the methyl group at the 5-*N* position with an ethyl group decreases the activity significantly, and the activity decreases further as the length of the *N*-5 alkyl chain increases. Thus the methyl,

Table 1. Bioactivity of Cryptolepine Analogs^a

compound	IC ₁₂ (1138), $\mu\text{g/mL}$	M109 cytotoxicity, μM
1	0.6	
2	0.5, 1.0, 5.0	
4	150	
5	1.5	
6		<1
7	40	<50
8	400	
16	80	
17	5	<10
18	80	
19	125	
20	90	
21	200	
22	5	<1
23	40	<10
24	125	
26	50	<10
27	50	<10
34	100	
36	400	
41	400	

^a Compounds **3**, **9**, **15**, **25**, **29–32**, and **37–40** had IC₁₂ values >400 $\mu\text{g/mL}$ in the 1138 yeast strain.



ethyl, propyl, and butyl analogues **1**, **7–9** gave IC₁₂ values of 0.6, 40, 400, and >400 $\mu\text{g/mL}$ in the 1138 assay.

Methylation at the N-10 position also causes a slight decrease in activity (compare **1** with IC₁₂ 0.6 $\mu\text{g/mL}$ and **17** with IC₁₂ 5 $\mu\text{g/mL}$). Increasing the size of the 10-substituent causes further loss of activity, as indicated by a comparison of **18**, **19**, and **20** (IC₁₂ 80, 125, and 90 $\mu\text{g/mL}$, respectively). On the other hand, N-acetylation (com-

pound **22**) gives a product which is as active as the N-methyl analogue **17** (IC₁₂ 5 $\mu\text{g/mL}$), suggesting that the N-acetyl analogue **22** may be partially hydrolyzed to **1**.

Substitution at C-11 with the polar electron-withdrawing groups COOH and CHO, compounds **3** and **25**, leads to greatly reduced activity (IC₁₂ > 400 $\mu\text{g/mL}$ in each case). However, the activity is reduced by a lesser amount when the C-11 substituent is carbomethoxy, hydroxymethyl, or methyl (compounds **23**, **24**, and **26**, with IC₁₂ values of 40, 125, and 50 $\mu\text{g/mL}$, respectively). These results indicate that the polarity and electron withdrawing characteristics of C-11-substituted groups may affect the activity.

Replacement of N-10 by an oxygen atom (compounds **38–41**) caused the loss of activity, with IC₁₂ values ≥ 400 $\mu\text{g/mL}$. Finally, both dimers **30** and **31** were inactive at 400 $\mu\text{g/mL}$, as was compound **32** with the 2-amino-2-methyl-1,3-propanediol side chain.

Selected analogues **6**, **7**, **17**, **22**, **23**, **26**, and **27** were tested for cytotoxicity to the M109 Madison lung carcinoma cell culture. The most active compounds were cryptolepine hydrotriflate (**6**) and the N-acetyl derivative **22**. As noted above, the activity of **22** may be due to a ready hydrolysis to the free base form. Compounds **6** and **22** were also tested in a panel of 25 cell lines; both compounds gave similar patterns, with the cell lines OVCAR-3 (IC₅₀ 0.5 μM) and A431 (IC₅₀ 0.34 μM) being the most sensitive and M109 (IC₅₀ 5.6 μM) and MLF (IC₅₀ 4.9 μM) being the least sensitive.

Compounds **6** and **22** were also subjected to analysis of their effect on cell cycle dependent growth disturbances. The results showed a G1 cell cycle arrest and apoptosis in A2780/p53wt cells at $5 \times \text{IC}_{50}$. Higher concentrations showed a dose-dependent increase in apoptosis. This effect appears to be p53 dependent since A2780/mutp53 cells showed no arrest in G1 and at $10 \times \text{IC}_{50}$ showed a slow cell cycle traverse with some arrest at G2/M. Apoptosis was present only at $20 \times \text{IC}_{50}$. These characteristics are typical of DNA-damaging agents.

In conclusion, cryptolepine was isolated by bioassay-guided fractionation of a mixture of two Surinamese plants, and its source was subsequently identified as *M. guyanensis*. Structure modification studies have shown that the N-5 methyl substitution is critical for activity, and that alkyl substitution on N-10 and replacement of 5-N-methyl with larger alkyl groups causes reduction of activity. Substitution on C-11 also led to decreased activity. The rest of the modifications, including dimers, 2-bromo substitutions, replacement of 10-NH with an oxygen, and addition of a side chain at the C-11 position all cause total loss of the yeast inhibitory activity. Besides cryptolepine hydrochloride itself (**1**), the most active compounds were **17** and **22**.

Experimental Section

General Experimental Procedures. NMR spectra were recorded in various deuterated solvents (CDCl₃, DMSO-*d*₆, and CD₃OD) on a Varian Unity 400 NMR instrument at 399.951 MHz for ¹H and 100.578 MHz for ¹³C, using standard Varian pulse sequence programs (*J* values are in Hz). LRMS were taken on a VG 7070E-HF at VPI&SU. Exact mass measurements were obtained at the Nebraska Center for Mass Spectrometry. Other conditions were as previously described.² All chemicals were purchased from Sigma or Aldrich and were used without further purification.

Plant Material. The plants *M. guyanensis* (A. DC) Pierre (Sapotaceae) and *Genipa americana* L. (Rubiaceae) were collected near Asindopo Village, Suriname, as a part of an effort to investigate plant mixtures as used by the tribal

healers; *M. guyanensis* was also collected as a single sample. Voucher specimens of the plants are located in the National Herbarium of Suriname, Paramaribo, Suriname. The mixed plants were dried, ground, and extracted with EtOAc followed by MeOH for 24 h each at BGVS, followed by separate evaporation of each solvent in vacuo to give EtOAc and MeOH-soluble fractions. The MeOH-soluble extract, coded as BGVS M950167, was active in the yeast bioassays described earlier.^{2c}

Isolation and Purification. Dried extract (500 mg) was dissolved in MeOH (2 mL) and passed through a Sephadex LH-20 column with elution with MeOH–EtOH (1:1). The active fractions 2 and 3 were combined and dried (155 mg) and then passed through a column of MCI gel eluted with H₂O, H₂O–MeOH (1:1), and MeOH. The active and pure fractions 4–7, eluted with H₂O–MeOH (1:1), were combined to give cryptolepine hydrochloride (**1**) (3 mg). Cryptolepine hydrochloride was also isolated by an acid–base partition as previously described.¹⁹

Subsequent investigation of an extract of *M. guyanensis* (BGVS M950147) using the same methods described above led to the isolation of cryptolepine from this plant alone.

Cryptolepine Hydrochloride (5-*N*-Methylquindolinium Chloride) (1**).** ¹H NMR (CD₃OD) δ 9.14 (s, 1H, H-11), 8.76 (d, J = 8.4, 1H, H-6), 8.67 (d, J = 9.6, 1H, H-4), 8.49 (d, J = 8.3, 1H, H-1), 8.18 (t, J = 7.9, 1H, H-3), 7.93–7.95 (m, 2H, H-2 and H-8), 7.83 (d, J = 8.6, 1H, H-9), 7.56 (td, J = 8.0, 0.8, 1H, H-7); ¹³C NMR (CD₃OD) δ 147.5 (s, C-9a), 139.7 (s, C-5a), 137.2 (s, C-4a), 135.4 (d, C-8), 134.0 (d, C-3), 131.2 (d, C-1), 128.5 (d, C-2), 128.5 (s, C-11a), 128.1 (s, C-10a), 126.9 (d, C-6), 126.3 (d, C-11), 123.0 (d, C-7), 118.4 (d, C-4), 115.4 (s, C-5b), 114.4 (d, C-9), 40.4 (5-*N*-CH₃); ROESY correlations, H-1 and H-11, H-4 and 5-*N*-CH₃, and H-6 and 5-*N*-CH₃. NMR assignments were based on ¹H–¹H COSY, HMQC, HMBC, and ROESY; EIMS m/z 233 (22%, [M – Cl]⁺), 232 (53%, [M – HCl]⁺), HRFABMS m/z 233.1075 [M – Cl]⁺ (calcd. for C₁₆H₁₃N₂, 233.1079).

Cryptolepine (2**).** Treatment of **1** with ammonium hydroxide gave compound **2** as a purple solid. The ¹H NMR data of **2** were consistent with literature data.¹⁹

Quindoline-11-carboxylic Acid (3**).** Compound **3** (990 mg) was prepared by treatment of isatin (685 mg) with indoxyl-1,3-diacetate (1 g) in aqueous KOH (4.15 g/18.5 mL) under argon at room temperature for 10 days and workup as previously described.^{11a} ¹H NMR (DMSO-*d*₆) δ 11.5 (s, 1H, 10-NH), 9.07 (dd, J = 7.6, 2.0, 1H), 8.37 (d, J = 7.6, 1H), 8.27 (dd, J = 8.4, 2.0, 1H), 7.77 (d, J = 8.4, 1H), 7.75–7.66 (m, 3H), 7.34 (t, J = 7.6, 1H); EIMS m/z 218 [M – CO₂]⁺ (calcd for C₁₅H₁₀N₂, 218).

Quindoline (4**).** Decarboxylation of compound **3** (1 g) was carried out by heating a vial containing compound **3** in an oil bath at 300 °C for 1.5 h.^{11a} Quindoline (**4**, 790 mg) was obtained as yellow crystals through sublimation on the vial walls (95%). ¹H and ¹³C NMR data were consistent with the data in the literature.^{9,20} EIMS: 218 [M]⁺, 190, 89; C₁₅H₁₀N₂.

5-*N*-Methylquindolinium Hydroiodide (5**).** Compound **5** was synthesized by treatment of quindoline (**4**) with iodomethane in anhydrous MeOH at 110 °C.¹¹ The ¹H NMR spectral data for **5** in CD₃OD were indistinguishable from those of compound **1**.

5-*N*-Methylquindolinium Triflate (6**).** Compound **6** was obtained by treatment of quindoline (**4**, 19 mg) with excess methyl triflate (30 μ L) in anhydrous toluene (3 mL) under argon for 24 h.⁹ Toluene was removed in vacuo, and the residue was washed with ether. The dry yellow solid was identified as compound **6** (18 mg). The ¹H NMR spectral data for **5** in CD₃OD were indistinguishable from those of compound **1**.

5-*N*-Ethylquindolinium Iodide (7**).** Compound **7** (10 mg) was synthesized from the *N*-ethylation of quindoline (**4**, 20 mg) using iodoethane (30 μ L) in anhydrous EtOH (2 mL) in a tightly closed vial at 140 °C for 4 h.^{10a} The product **7** and starting material **4** were obtained in a 1:1 ratio and were separated by chromatography on an alumina column eluted with CH₂Cl₂, then CH₂Cl₂–MeOH (10:1). Compound **7** was obtained in the CH₂Cl₂–MeOH fraction, and quindoline (**4**) was recovered in the CH₂Cl₂ fraction. ¹H NMR (CDCl₃) δ 9.50

(s, 1H, H-11), 8.36 (d, J = 7.6, 1H), 8.31 (d, J = 8.8, 1H), 8.26 (d, J = 8.8, 1H), 8.11 (t, J = 8.0, 1H), 8.04 (t, J = 8.0, 1H), 7.86 (t, J = 7.6, 1H), 7.84 (d, J = 8.8, 1H, H-9), 7.48 (t, J = 8.0, 1H, H-7), 5.50 (q, J = 7.6, 2H, –CH₂–), 2.01 (t, J = 7.6, 3H, –CH₃); ¹H NMR (CD₃OD) δ 9.18 (s, 1H, H-11), 8.70 (d, J = 8.8, 1H, H-4), 8.62 (d, J = 8.8, 1H, H-6), 8.51 (d, J = 8.4, 1H, H-1), 8.20 (td, J = 8.0, 1.2, 1H, H-3), 7.95 (m, 2H, H-2 and H-8), 7.84 (d, J = 8.4, 1H, H-9), 7.59 (td, J = 8.0, 1.2, 1H, H-7), 5.62 (q, J = 7.6, 2H, –CH₂–), 1.91 (t, J = 7.6, 3H, –CH₃); EIMS m/z 218 [M – I – Et]⁺; FABMS 247 [M – I]⁺, 219.

5-*N*-Propylquindolinium Iodide (8**).** Quindoline (**4**, 15 mg) was mixed with excess propyl iodide (100 μ L) and DMF (200 μ L) and heated at 150 °C for 24 h in a closed vial. The solvent was removed under high vacuum, and the product isolated using an alumina column as described for compound **7** to give compound **8** (5 mg) in the CH₂Cl₂–MeOH eluent. ¹H NMR (CD₃OD) δ 9.18 (s, 1H, H-11), 8.69 (d, J = 9.2, 1H, H-4), 8.50 (d, J = 8.4, 1H, H-6), 8.49 (d, J = 8.4, 1H, H-1), 8.19 (td, J = 8.4, 1.2, 1H, H-3), 7.96–7.91 (m, 2H, H-2 and H-8), 7.82 (d, J = 8.4, 1H, H-9), 7.59 (td, J = 8.4, 1.2, 1H, H-7), 5.51 (t, J = 7.6, 2H, –CH₂–), 2.30 (sextet, J = 7.6, 2H, –CH₂–), 1.34 (t, J = 7.6, 3H, –CH₃); EIMS m/z 260 [M – HI]⁺, 218 [M – PrI]⁺; HREIMS m/z 260.1299 (calcd for C₁₈H₁₇N₂, 260.1313).

5-*N*-Butylquindolinium Hydrobromide (9**).** Treatment of quindoline (**4**, 23 mg) with butyl bromide as described for compound **8** gave compound **9** (7 mg). ¹H NMR (CD₃OD) δ 9.09 (s, 1H, H-11), 8.58 (d, J = 9.2, 1H, H-4), 8.42 (d, J = 8.4, 2H, H-1 and H-6), 8.14 (td, J = 8.0, 1.6, 1H, H-3), 7.89 (td, J = 8.4, 1.6, 2H, H-2 and H-8), 7.77 (d, J = 8.4, 1H, H-9), 7.54 (t, J = 8.4, 1H, H-7), 5.45 (t, J = 7.6, 2H, –CH₂–), 2.15 (quintet, J = 7.6, 2H, –CH₂–), 1.75 (sextet, J = 7.6, 2H, –CH₂–), 1.11 (t, J = 7.6, 3H, –CH₃); ¹³C NMR (MeOD) δ 147.6 (s), 138.5 (s), 136.3 (s), 135.3 (d), 135.0 (s), 134.2 (d), 131.3 (d), 128.4 (d), 128.1 (s), 126.4 (d), 125.9 (d), 123.3 (d), 118.1 (d), 114.5 (d), 114.3 (s), 52.8 (t), 31.4 (t), 20.9 (t), 14.2 (q); EIMS m/z 274 [M – HBr]⁺, 218 [M – BuBr]⁺, 190, 88; HREIMS m/z 274.1472 (calcd for C₁₉H₁₉N₂, 274.1470).

10-*N*-Methylquindoline (10**).** The method described in the literature was used and summarized as below.⁹ Quindoline (**4**, 15 mg) mixed with BaO (45 mg) and KOH (15 mg) in acetone (5 mL) was refluxed for 1 h. Excess iodomethane (60 μ L) was added to the cooled residue and the mixture refluxed for an additional 4 h; the excess reagent was then removed in a vacuum. The organic material was extracted with ether, dried over MgSO₄, and the solution evaporated to obtain compound **10** (15 mg). ¹H NMR (CDCl₃) δ 8.58 (d, J = 8.4, 1H), 8.36 (d, J = 9.2, 1H), 7.95 (d, J = 8.4, 1H), 7.92 (s, 1H, H-11), 7.65 (m, 2H), 7.54 (t, J = 8.4, 1H), 7.40 (d, J = 8.8, 1H), 7.34 (t, J = 8.4, 1H), 3.86 (s, 3H, 10-*N*-CH₃); EIMS m/z 232 [M]⁺, 217 [M – CH₃]⁺, 190, 89; HREIMS m/z 232.0993 (calcd for C₁₆H₁₂N₂, 232.1000).

10-*N*-Ethylquindoline (11**).** Using iodoethane as alkylating agent (30 μ L), compound **11** (5 mg, 95% yield) was synthesized using the methods described for compound **10**. ¹H NMR (CDCl₃) δ 8.65 (d, J = 8.0, 1H), 8.40 (d, J = 7.9, 1H), 8.01 (s, 1H, H-11), 7.98 (d, J = 8.3, 1H), 7.67 (m, 2H), 7.56 (t, J = 7.9, 1H), 7.44 (d, J = 8.3, 1H), 7.35 (t, J = 7.9, 1H), 4.42 (q, J = 7.2, 2H, –CH₂–), 1.49 (t, J = 7.2, 3H, –CH₃); EIMS m/z 246 [M]⁺, 231 [M – CH₃]⁺, 217 [M – Et]⁺, 190, 89; HREIMS m/z 246.1150 (calcd for C₁₇H₁₄N₂, 246.1157).

10-*N*-Propylquindoline (12**).** Using propyl iodide as alkylating agent (30 μ L), compound **12** (5 mg, 95% yield) was synthesized using the methods described for compound **10**. ¹H NMR (CDCl₃) δ 8.62 (d, J = 8.3, 1H), 8.38 (d, J = 7.9, 1H), 7.99 (s, 1H, H-11), 7.97 (d, J = 8.4, 1H), 7.66 (m, 2H), 7.56 (t, J = 7.9, 1H), 7.44 (d, J = 8.3, 1H), 7.34 (t, J = 7.9, 1H), 4.32 (t, J = 7.2, 2H, –CH₂–), 1.98 (sextet, J = 7.2, 2H, –CH₂–), 1.02 (t, J = 7.2, 3H, –CH₃); EIMS m/z 260 [M]⁺, 231 [M – Et]⁺, 190; HREIMS m/z 260.1311 (calcd for C₁₈H₁₆N₂, 260.1313).

10-*N*-Butylquindoline (13**).** Using butyl bromide as alkylating agent (30 μ L), compound **13** (5 mg, 95% yield) was synthesized using the methods described for compound **10**. ¹H NMR (CDCl₃) δ 8.65 (d, J = 8.3, 1H), 8.41 (d, J = 7.9, 1H), 8.00 (s, 1H, H-11), 7.98 (d, J = 8.4, 1H), 7.67 (m, 2H), 7.56 (t, J = 7.9, 1H), 7.44 (d, J = 8.3, 1H), 7.35 (t, J = 7.9, 1H), 4.36

(t, $J = 7.2$, 2H, $-\text{CH}_2-$), 1.92 (quintet, $J = 7.2$, 2H, $-\text{CH}_2-$), 1.44 (sextet, $J = 7.2$, 2H, $-\text{CH}_2-$), 0.97 (t, $J = 7.2$, 3H, $-\text{CH}_3$); EIMS m/z 274 $[\text{M}]^+$, 231 $[\text{M} - \text{propyl}]^+$, 217, 190, 89; HREIMS m/z 274.1471 (calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2$, 274.1470).

10-N-Allylquindoline (14). Using allyl bromide as alkylating agent (30 μL), compound **14** (2 mg, 95% yield) was synthesized using the methods described for compound **10**. ^1H NMR (CDCl_3) δ 8.64 (d, $J = 8.3$, 1H), 8.42 (d, $J = 7.9$, 1H), 7.98 (s, 1H, H-11), 7.97 (d, $J = 8.4$, 1H), 7.67 (m, 2H), 7.56 (t, $J = 7.6$, 1H), 7.41 (d, $J = 8.3$, 1H), 7.36 (t, $J = 7.6$, 1H), 6.04 (dddd, $J = 17$, 10, 5.0, 5.0, 1H, $=\text{CH}-$), 5.23 (brd, $J = 10$, 1H, $=\text{CH}_2$), 5.10 (brd, $J = 17$, 1H, $=\text{CH}_2$), 4.97 (brd, $J = 5.0$, 2H, $-\text{CH}_2-$); EIMS m/z 258 $[\text{M}]^+$, 231 $[\text{M} - \text{CH}=\text{CH}_2]^+$, 217 $[\text{M} - \text{CH}_2\text{CH}=\text{CH}_2]^+$, 190.

10-N-Benzylquindoline (15). Using benzyl bromide as alkylating agent (30 μL), compound **15** (4 mg, 95% yield) was synthesized using the methods described for compound **10**. ^1H NMR (CDCl_3) δ 8.70 (d, $J = 8.3$, 1H), 8.43 (d, $J = 7.9$, 1H), 7.97 (s, 1H, H-11), 7.92 (d, $J = 8.0$, 1H), 7.69 (t, $J = 7.6$, 1H), 7.64 (t, $J = 8.3$, 1H), 7.55 (t, $J = 7.6$, 1H), 7.41 (d, $J = 8.2$, 1H), 7.38–7.18 (m, 6H), 5.58 (s, 2H); EIMS m/z 308 $[\text{M}]^+$, 216 $[\text{M} - \text{C}_7\text{H}_8]^+$.

10-N-Acetylquindoline (16). Quindoline (**4**, 8 mg) was stirred with acetic anhydride (0.5 mL) and pyridine (0.5 mL) at room temperature for 48 h. The product **16** (9 mg) was obtained after removing excess reagent in vacuo, and passing through an alumina column with elution with CH_2Cl_2 . ^1H NMR (CD_3OD) δ 9.00 (s, 1H, H-11), 8.50 (d, $J = 8.0$, 1H), 8.27 (d, $J = 8.4$, 1H), 8.13 (d, $J = 8.0$, 1H), 7.99 (d, $J = 8.4$, 1H), 7.75 (t, $J = 7.6$, 1H), 7.66 (t, $J = 7.6$, 1H), 7.59 (t, $J = 7.6$, 1H), 7.51 (t, $J = 7.6$, 1H), 2.95 (s, 3H, $-\text{N}-\text{CO}-\text{CH}_3$); ^{13}C NMR (CD_3OD) δ 169.7 (s), 147.3 (s), 145.9 (s), 141.4 (s), 131.3 (s), 130.6 (d), 128.8 (d), 128.6 (d), 128.5 (d), 127.2 (s), 126.1 (d), 125.6 (s), 124.4 (d), 122.0 (d), 121.5 (d), 115.7 (d), 27.6 (q); FABMS m/z 261 $[\text{M} + 1]^+$, 219; HREIMS m/z 260.0941 (calcd for $\text{C}_{17}\text{H}_{12}\text{N}_2\text{O}$, 260.0950).

5,10-N,N-Dimethylquindolinium Triflate (17). Compound **10** (7.5 mg) in anhydrous toluene was treated with excess methyl triflate under argon at room temperature for 24 h. The excess reagent was removed in a vacuum, and compound **17** (7 mg) was obtained after washing with ether and drying. ^1H NMR (CD_3OD) δ 9.36 (s, 1H, H-11), 8.81 (d, $J = 8.4$, 1H, H-6), 8.69 (d, $J = 8.4$, 1H, H-4), 8.53 (d, $J = 8.4$, 1H, H-1), 8.21 (td, $J = 8.4$, 0.8, 1H, H-3), 8.04 (t, $J = 8.0$, 1H, H-8), 7.97 (m, 2H, H-2 and H-9), 7.62 (t, $J = 8.4$, 1H, H-7), 5.13 (s, 3H, 5- N - CH_3), 4.21 (s, 3H, 10- N - CH_3); ^{13}C NMR (CD_3OD) δ 148.3 (s), 135.8 (s), 135.6 (d), 134.0 (d), 133.3 (s), 131.2 (d), 130.2 (s), 128.7 (d), 127.9 (s), 127.2 (d), 124.7 (d), 123.1 (d), 118.4 (d), 115.3 (s), 112.3 (d), 40.8 (q), 30.2 (q); EIMS m/z 247 $[\text{M} - \text{Tf}]^+$, 233 $[\text{M} - \text{Tf} - \text{CH}_2]^+$ (calcd for $\text{C}_{17}\text{H}_{15}\text{N}_2$, 247).

5-N-Methyl-10-N-ethylquindolinium Triflate (18). Using compound **11** (2.5 mg) as starting material, compound **18** (2.3 mg) was synthesized using the methods described for compound **17**. ^1H NMR (CD_3OD) δ 9.39 (s, 1H, H-11), 8.81 (d, $J = 8.0$, 1H, H-6), 8.68 (d, $J = 8.8$, 1H, H-4), 8.52 (d, $J = 8.4$, 1H, H-1), 8.20 (td, $J = 8.0$, 1.2, 1H, H-3), 8.03 (t, $J = 8.0$, 1H, H-8), 7.98 (m, 2H, H-2 and H-9), 7.61 (td, $J = 8.0$, 0.8, 1H, H-7), 5.12 (s, 3H, 5- N - CH_3), 4.78 (q, $J = 7.2$, 2H, $-\text{CH}_2-$), 1.56 (t, $J = 7.2$, 3H, $-\text{CH}_3$); EIMS m/z 261 $[\text{M} - \text{Tf}]^+$, 246 $[\text{M} - \text{Tf} - \text{CH}_3]^+$ (calcd for $\text{C}_{18}\text{H}_{17}\text{N}_2$, 261).

5-N-Methyl-10-N-propylquindolinium Triflate (19). Compound **19** (2.1 mg) was synthesized from **12** (2.5 mg) using the methods described for compound **17**. ^1H NMR (CD_3OD) δ 9.40 (s, 1H, H-11), 8.81 (d, $J = 8.4$, 1H, H-6), 8.69 (d, $J = 8.8$, 1H, H-4), 8.53 (d, $J = 8.4$, 1H, H-1), 8.20 (td, $J = 8.0$, 1.6, 1H, H-3), 8.03 (td, $J = 8$, 1.2, 1H, H-8), 7.98 (m, 2H, H-2 and H-9), 7.61 (td, $J = 8.0$, 1.6, 1H, H-7), 5.13 (s, 3H, N - CH_3), 4.70 (t, $J = 7.2$, 2H, $-\text{CH}_2-$), 2.04 (sextet, $J = 7.2$, 2H, $-\text{CH}_2-$), 1.04 (t, $J = 7.2$, 3H, $-\text{CH}_3$); EIMS m/z 275 $[\text{M} - \text{Tf}]^+$, 260 $[\text{M} - \text{Tf} - \text{Me}]^+$, 231 $[\text{M} - \text{Tf} - \text{Et}]^+$ (calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2$, 275).

5-N-Methyl-10-N-butylquindolinium Triflate (20). Compound **20** (2.0 mg) was synthesized from **13** (2.5 mg) using the methods described for compound **17**. ^1H NMR (CD_3OD) δ 9.19 (s, 1H, H-11), 8.59 (d, $J = 8.4$, 1H, H-6), 8.42 (d, $J = 8.8$, 1H, H-4), 8.39 (d, $J = 8.8$, 1H, H-1), 7.96 (t, $J = 8.0$, 1H, H-3), 7.87

(t, $J = 8.0$, 1H, H-8), 7.66 (t, $J = 8.0$, 1H, H-2), 7.60 (d, $J = 8.4$, 1H, H-9), 7.25 (t, $J = 8.0$, 1H, H-7), 5.00 (s, 3H, 5- N - CH_3), 4.58 (t, $J = 7.6$, 2H, $-\text{CH}_2-$), 1.88 (quintet, $J = 7.6$, 2H, $-\text{CH}_2-$), 1.40 (sextet, $J = 7.6$, 2H, $-\text{CH}_2-$), 0.93 (t, 3H, $-\text{CH}_3$); EIMS m/z 289 $[\text{M} - \text{Tf}]^+$, 275 $[\text{M} - \text{Tf} - \text{CH}_2]^+$, 245, 232 $[\text{M} - \text{Tf} - \text{CH}_2 - \text{propyl}]^+$ (calcd for $\text{C}_{20}\text{H}_{21}\text{N}_2$, 289).

5-N-Methyl-10-N-allylquindolinium Triflate (21). Compound **21** (0.6 mg) was synthesized from **14** (1.0 mg) using the methods described for compound **17**. ^1H NMR (CD_3OD) δ 9.33 (s, 1H, H-11), 8.82 (d, $J = 8.4$, 1H, H-6), 8.69 (d, $J = 8.8$, 1H, H-4), 8.51 (d, $J = 8.0$, 1H, H-1), 8.21 (td, $J = 8.8$, 1.2, 1H, H-3), 8.02 (td, $J = 8.0$, 1.2, 1H, H-8), 7.97 (t, $J = 8.0$, 1H, H-2), 7.92 (d, $J = 8.4$, 1H, H-9), 7.62 (t, $J = 8.0$, 1H, H-7), 6.15 (dddd, $J = 17$, 10, 5, 5, 1H, $=\text{CH}-$), 5.36 (brd, 5.0, 2H, $-\text{CH}_2-$), 5.26 (d, $J = 10$, 1H, $=\text{CH}_2$), 5.11 (d, $J = 17$, 1H, $=\text{CH}_2$), (s, 3H, 5- N - CH_3); EIMS m/z 273 $[\text{M} - \text{Tf}]^+$, 258 $[\text{M} - \text{Tf} - \text{CH}_3]^+$, 231 $[\text{M} - \text{Tf} - \text{C}_3\text{H}_6]^+$, 217 $[\text{M} - \text{Tf} - \text{C}_4\text{H}_8]^+$ (calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2$, 273).

5-N-Methyl-10-N-acetylquindolinium Chloride (22). Compound **1** (1 mg) was stirred with acetic anhydride (0.3 mL) and pyridine (0.3 mL) for 24 h. The product **22** (1 mg) was obtained after removing excess reagent in a vacuum, extraction with 1 mL of $\text{MeOH}-\text{H}_2\text{O}$ (1:1), and drying. ^1H NMR (CDCl_3) δ 10.02 (s, 1H, H-11), 8.77 (d, $J = 8.2$, 1H), 8.59 (d, $J = 9.0$, 1H), 8.40 (d, $J = 8.5$, 1H), 8.27 (d, $J = 8.5$, 1H), 8.20 (t, $J = 8.5$, 1H), 7.97 (t, $J = 8.2$, 1H), 7.91 (t, $J = 7.6$, 1H), 7.71 (t, $J = 8.2$, 1H), 5.26 (s, 3H, 5- N - CH_3), 3.16 (s, 3H, COCH_3); FABMS m/z 275 $[\text{M} - \text{Cl}]^+$, 233 $[\text{M} - \text{Cl} - \text{COCH}_2]^+$, 218 $[\text{M} - \text{Cl} - \text{Ac} - \text{CH}_3]^+$ (calcd for $\text{C}_{18}\text{H}_{15}\text{N}_2\text{O}$, 275).

Methyl Quindoline-11-carboxylate (23). Compound **3** (30 mg) was treated with excess diazomethane in ether, and the mixture was stirred at room temperature for 3 h until the starting material had dissolved. The solvent was removed, and the product purified by chromatography on alumina with elution by CH_2Cl_2 to give **23** (31 mg). ^1H NMR (CDCl_3) δ 9.73 (bs, 1H, 10-NH), 9.04 (dd, $J = 7.6$, 2.4, 1H), 8.49 (d, $J = 7.6$, 1H), 8.37 (dd, $J = 7.6$, 2.0, 1H), 7.67 (m, 2H), 7.60 (td, $J = 7.9$, 1.2, 1H), 7.46 (d, $J = 8$, 1H), 7.35 (td, $J = 8$, 1.2, 1H), 4.16 (s, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 168.1 (s), 147.7 (s), 144.3 (s), 143.5 (s), 133.8 (s), 130.5 (d), 130.1 (d), 127.4 (d), 126.2 (d), 125.0 (d), 123.6 (s), 122.2 (d), 121.5 (s), 121.0 (d), 111.2 (d), 109.1 (s), 52.5 (q); HREIMS m/z 276.0895 (calcd for $\text{C}_{17}\text{H}_{12}\text{N}_2\text{O}_2$, 276.0899).

11-Hydroxymethylquindoline (24). Methylquindoline-11-carboxylate (**23**, 23 mg) was treated with LAH (30 mg) in THF (5 mL) under reflux for 30 min. The reaction residue was cooled, excess LAH allowed to settle out, and the supernatant transferred to another flask and treated with EtOAc (25 mL) and MeOH (1 mL). After filtration, the filtrate was evaporated to give compound **24** (21 mg). ^1H NMR (CDCl_3) δ 8.45 (ddd, $J = 8.0$, 0.8, 0.8, 1H), 8.27 (ddd, $J = 8.4$, 0.8, 0.8, 1H), 8.20 (ddd, $J = 8.0$, 0.8, 0.8, 1H), 7.67 (td, $J = 8.0$, 1.2, 1H), 7.63–7.54 (m, 3H), 7.28 (td, $J = 8.0$, 1.2, 1H), 5.49 (s, 2H, CH_2OH); ^1H NMR (CD_3OD) δ 8.56 (d, $J = 8.0$, 1H), 8.52 (d, $J = 8.4$, 1H), 8.35 (d, $J = 8.4$, 1H), 8.05 (td, $J = 8.0$, 1.2, 1H), 7.87 (t, $J = 8.4$, 2H), 7.81 (d, $J = 8.4$, 1H), 7.48 (td, $J = 8.0$, 1.2, 1H), 5.74 (s, 2H, $-\text{CH}_2\text{OH}$); ^{13}C NMR (CD_3OD) δ 147.3 (s), 145.8 (s), 144.7 (s), 132.8 (s), 131.3 (d), 129.1 (d), 127.5 (d), 126.3 (d), 126.1 (s), 125.5 (s), 124.3 (d), 122.8 (d), 121.8 (s), 120.7 (d), 112.5 (d), 58.7 (t); EIMS m/z 248 $[\text{M}]^+$, 230 $[\text{M} - \text{H}_2\text{O}]^+$, 218 $[\text{M} - \text{CH}_2\text{O}]^+$, 190 (calcd for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}$, 248).

11-Formylquindoline (25). Compound **24** (10 mg) was treated with PDC (30 mg) in CH_2Cl_2 at room temperature for 12 h. The reaction mixture was passed through an alumina column eluted with n -hexanes– EtOAc (3:1), and fractions containing the desired compound were combined and dried to give **25** (5 mg). Continued elution with MeOH gave recovered starting material **24** (4 mg). ^1H NMR (CDCl_3 – CD_3OD , 10:1) δ 11.19 (s, 1H, COH), 8.67 (m, 1H), 8.44 (d, $J = 7.6$, 1H, H-6), 8.32 (m, 1H), 7.68 (m, 2H, H-2 and H-3), 7.59 (t, $J = 8.0$, 1H, H-8), 7.50 (d, $J = 8.0$, 1H, H-9), 7.34 (t, $J = 8.0$, 1H, H-7); ^{13}C NMR (CDCl_3 – CD_3OD , 10:1) δ 191.6 (d), 148.3 (s), 144.4 (s), 143.3 (s), 133.1 (s), 131.0 (s), 130.8 (d), 129.8 (d), 127.8 (d), 126.6 (d), 124.1 (s), 122.2 (d), 121.6 (d), 120.4 (s), 119.9 (d),

111.7 (d); EIMS m/z 246 $[M]^+$, 217 $[M - COH]^+$; HREIMS m/z 246.0794 (calcd for $C_{16}H_{10}N_2O$, 246.0793).

11-Methylquindoline (26). Treatment of methylquindoline-11-carboxylate (**23**, 15 mg) with LAH (60 mg) in THF (5 mL) under reflux for 5 h, followed by chromatography on alumina with CH_2Cl_2 -MeOH (50:1) as eluent gave **26** (8 mg). 1H NMR ($CDCl_3$ - CD_3OD , 10:1) δ 8.4 (d, $J = 8.8$, 1H), 8.22 (d, $J = 8.8$, 1H), 7.98 (dd, $J = 9.2$, 0.8, 1H), 7.613 (td, $J = 8.0$, 1.2, 1H), 7.49 (td, $J = 8.0$, 1.2, 1H), 7.33 (d, $J = 9.2$, 1H), 7.16 (td, $J = 8.8$, 1.2, 1H), 2.78 (s, 3H, $-CH_3$); ^{13}C NMR ($CDCl_3$ - CD_3OD , 10:1) δ 143.7 (s), 142.2 (s), 132.0 (s), 130.0 (d), 127.4 (d), 126.7 (d), 125.8 (s), 124.8 (d), 123.5 (s), 122.9 (d and s, 2C), 122.2 (d), 120.3 (s), 119.8 (d), 111.1 (d), 12.4 (q); EIMS m/z 233 $[MH]^+$, 232 $[M]^+$; HREIMS m/z 232.1001 (calcd for $C_{16}H_{12}N_2$, 232.1000).

Carbamate 27. Compound **24** (3 mg) was treated with excess 1,1'-carbonyldiimidazole (15 mg) and imidazole (1 mg) in CH_2Cl_2 (3 mL) at room temperature for 24 h. The reaction residue was purified by PTLC on alumina PTLC with development by CH_2Cl_2 . To give carbamate **27** (1.5 mg). 1H NMR ($CDCl_3$) δ 8.46 (d, $J = 8.0$, 1H), 8.40 (d, $J = 8.4$, 1H), 8.38 (d, $J = 8.4$, 1H), 7.80 (t, $J = 8.0$, 1H), 7.75 (m, 2H), 7.69 (t, $J = 8.0$, 1H), 7.57 (t, $J = 8.0$, 1H), 6.24 (s, 2H, $-CH_2O-$); EIMS m/z 274 $[M]^+$, 230 $[M - CO_2]^+$ (calcd for $C_{17}H_{10}N_2O_2$, 274).

Quindoline-11-carbonyl Chloride (28). Quindoline-11-carboxylic acid (**5**) was refluxed with $SOCl_2$ for 2 h, and then excess $SOCl_2$ was removed in vacuo. The dried material was used directly without further purification.

2-Hydroxyethyl Quindoline-11-carboxylate (29). Quindoline-11-carbonyl chloride (**28**, 10 mg) was heated in ethylene glycol (0.5 mL) at 110 °C for 1 h. The cooled reaction mixture was filtered and the residue was washed with cold acetone to give **29** (9 mg). 1H NMR (CD_3OD) δ 9.06 (d, $J = 8.5$, 1H), 8.57 (d, $J = 8.1$, 1H), 8.38 (d, $J = 8.6$, 1H), 8.04 (t, $J = 7.4$, 1H), 7.90 (t, $J = 8.3$, 2H), 7.76 (d, $J = 8.3$, 1H), 7.51 (t, $J = 7.6$, 1H), 4.80 (t, $J = 4.7$, 2H, $-CO_2CH_2-$), 4.08 (t, $J = 4.7$, 2H, $-CH_2OH$); ^{13}C NMR δ 165.3 (s), 147.8 (s), 141.5 (s), 136.3 (d), 136.2 (s), 134.9 (s), 132.3 (d), 129.7 (d), 127.4 (d), 124.7 (d), 123.4 (d), 122.2 (s), 121.8 (d), 115.2 (s), 114.3 (d), 69.2 (t), 60.7 (t); FABMS m/z 307 $[MH]^+$ (calcd for $C_{18}H_{15}N_2O_3$, 307).

1,2-Ethanediol 1,2-Bis(quindoline-11-carboxylate) (30). A mixture of compound **29** (1.2 mg), compound **3** (3 mg), DCC (15 mg), 4-pyrrolidinylpyridine (trace), and CH_2Cl_2 (2 mL) was stirred at room temperature for 12 h. The excess of compound **3** was sparingly soluble in CH_2Cl_2 , and was separated easily by filtration. The reaction residue was purified by PTLC on alumina with development by CH_2Cl_2 to give compound **30** (2 mg). 1H NMR ($CDCl_3$) δ 9.87 (s, 2H, NH-10 and -10'), 9.12 (dd, $J = 8.8$, 0.8, 2H), 8.44 (d, $J = 8.0$, 2H), 8.33 (dd, $J = 8.0$, 0.4, 2H), 7.62 (td, $J = 8.4$, 1.2, 2H), 7.48-7.58 (m, 4H), 7.323 (t, $J = 8.0$, 2H), 7.21 (d, $J = 8.0$, 2H), 5.17 (s, 4H, $-O-CH_2-CH_2-O-$); ^{13}C NMR δ 167.4 (s), 147.9 (s), 144.3 (s), 143.6 (s), 139.8 (s), 133.7 (s), 130.6 (d), 130.3 (d), 127.6 (d), 126.2 (d), 124.7 (d), 123.6 (s), 122.1 (d), 121.5 (s), 121.1 (d), 111.2 (d), 63.5 (t); FABMS m/z 551 $[MH]^+$, 307 (calcd for $C_{34}H_{23}N_4O_4$, 551).

Bisquindoline (31). Compound **31** was prepared as previously described.^{11a} 1H NMR ($CDCl_3$) δ 9.05 (d, $J = 8.8$, 2H), 8.65 (d, $J = 8.0$, 2H), 8.48 (d, $J = 8.4$, 2H), 7.87-7.74 (m, 8H), 7.38 (t, $J = 8.0$, 2H); ^{13}C NMR ($CDCl_3$) δ 166.9 (s), 145.3 (s), 135.3 (s), 132.6 (d), 132.3 (d), 129.9 (s), 128.0 (d), 127.4 (d), 125.5 (s), 125.4 (d), 123.4 (s), 123.3 (s), 123.0 (d), 120.9 (d), 117.5 (s), 113.0 (d).

2-Methyl-2-[11-(aminomethyl)quindoline]-1,3-propanediol (32). A mixture of aldehyde **25** (2 mg), anhydrous $MgSO_4$ (40 mg), and 2-amino-2-methyl-1,3-propanediol (10 mg) was dissolved in CH_2Cl_2 -anhydrous MeOH (5:1, 2 mL) and the mixture stirred at room temperature for 24 h. The reaction residue was treated with an additional 4 mL of solvent (CH_2Cl_2 -MeOH, 5:1), then filtered to remove $MgSO_4$ and excess amine. The filtrate was evaporated in vacuo, and the dried residue was dissolved in 1.5 mL of MeOH. $NaB(CN)H_3$ (15 mg) was added, and the solution was stirred at room temperature for 1 h. The MeOH in the reaction mixture was then removed in vacuo, and the product was partitioned between EtOAc and

H_2O (3 mL each). The EtOAc layer was dried (Na_2SO_4), and the EtOAc was removed in a vacuum. The residue was purified by PTLC on alumina and developed by $CHCl_3$ -MeOH (10:1). The product band gave compound **32** (1.2 mg). 1H NMR (CD_3OD) δ 8.45 (dd, $J = 7.6$, 0.8, 1H), 8.38 (d, $J = 8.4$, 1H), 8.21 (d, $J = 8.4$, 1H), 7.67 (td, $J = 8.0$, 1.2, 1H), 7.64-7.58 (m, 2H), 7.54 (dd, $J = 8.0$, 0.8, 1H), 7.29 (td, $J = 8.0$, 1.2, 1H), 4.57 (s, 2H, $-CH_2-N$), 3.68 (s, 4H, $2 \times -CH_2OH$), 1.21 (s, 3H, $-CH_3$); ^{13}C NMR (CD_3OD) δ 147.0 (s), 145.7 (s), 144.8 (s), 133.6 (s), 131.2 (d), 129.3 (d), 127.5 (d), 126.6 (s), 126.4 (d), 125.6 (s), 124.2 (d), 122.8 (d), 122.0 (s), 120.8 (d), 112.5 (d), 66.2 (t, 2C), 59.1 (s), 39.2 (t), 18.7 (q); FABMS m/z 336 $[MH]^+$, 231 $[M - side\ chain]^+$ (calcd for $C_{20}H_{22}N_3O_2$, 336).

Methyl 2-Bromoquindoline-11-carboxylate (34). 2-Bromoquindoline-11-carboxylic acid (**33**) (850 mg) was synthesized in crude form as described for compound **3** from 5-bromoisatin (685 mg) and indoxyl-1,3-diacetate (1 g) in aqueous KOH (4.15 g/18.5 mL) under argon at room temperature for 10 days. ^{13}C NMR ($DMSO-d_6$) δ 168.2, 145.0, 143.5, 132.7, 132.0, 131.3, 130.9, 129.7, 129.3, 127.2, 126.5, 125.4, 124.1, 121.8, 120.8, 113.0; EIMS m/z 342, 340 $[M]^+$, 324, 322 $[M - H_2O]^+$, 296, 294, 262, 244, 216, 215, 188 (calcd for $C_{16}H_9N_2O_2Br$, 342, 340). Treatment of crude **33** (15 mg) with excess CH_2N_2 as described for **23** gave **34** (16 mg). 1H NMR ($CDCl_3$) δ 9.75 (bs, 1H, 10-NH), 9.23 (d, $J = 2$, 1H), 8.45 (d, $J = 8$, 1H), 8.20 (d, $J = 8.8$, 1H), 7.73 (dd, $J = 8.8$, 2.4, 1H), 7.63 (td, $J = 7.6$, 1.2, 1H), 7.47 (d, $J = 8$, 1H), 7.37 (td, $J = 8$, 0.8, 1H), 4.19 (s, 3H, $COOCH_3$); EIMS m/z 356, 354 $[MH]^+$, 324, 322 $[M - HOCH_3]^+$, 296, 294 $[M - C_2H_4O_2]^+$, 276, 244, 215 $[M - HCO_2CH_3 - Br]^+$, 216, 188 (calcd for $C_{17}H_{12}N_2O_2Br$, 356, 354).

2-Bromoquindoline-11-carbonyl Chloride (35). Compound **33** (10 mg) was mixed with $SOCl_2$ (1 mL) and heated at 70 °C for 2 h. After cooling to room temperature, excess $SOCl_2$ was quickly removed at room temperature in vacuo. The residue was used directly without further purification.

2-Bromoquindoline-11-carboxamide (36). Freshly prepared **35** (12 mg) was treated with aqueous ammonia (37%, 0.5 mL). The dried residue containing compound **36** (8 mg) was obtained after removal of excess ammonia and water in vacuo, and washed with $CHCl_3$ and MeOH. 1H NMR ($DMSO-d_6$) δ 11.54 (s, 1H, 10-NH), 8.50 and 8.26 (2 $\times$ bs, 2H, $-CONH_2$), 8.33 (m, 2H, H-1 and H-6), 8.15 (d, $J = 8.8$, 1H, H-4), 7.76 (dd, $J = 8.8$, 2.3, 1H, H-3), 7.62 (m, 2H, H-8 and H-9), 7.31 (t, $J = 7.2$, 1H, H-7); ^{13}C NMR ($DMSO-d_6$) δ 166.6 (s), 146.9 (s), 144.7 (s), 141.6 (s), 135.3 (s), 131.3 (d), 130.5 (d), 129.0 (d), 126.3 (d), 123.7 (s), 121.4 (d), 120.4 (s), 120.0 (d), 119.6 (s), 118.7 (s), 112.1 (d); EIMS m/z 341, 339 $[M]^+$, 324, 322 $[M - NH_3]^+$, 296, 294 $[M - CONH_3]^+$, 215 $[M - Br - CONH_3]^+$ (calcd for $C_{16}H_{10}N_3OBr$, 341, 339).

Benzofuro[3,2-b]quinolin-6(11H)one (37). Compound **37** (220 mg) was synthesized by a literature procedure.^{18c} 1H NMR ($DMSO-d_6$) δ 8.30 (d, $J = 8.0$, 1H), 8.16 (d, $J = 8.0$, 1H), 7.73 (d, $J = 8.4$, 1H), 7.61 (d, $J = 8.0$, 1H), 7.52 (t, $J = 8.4$, 1H), 7.45 (t, $J = 8.4$, 1H), 7.33 (t, $J = 8.4$, 1H), 7.12 (t, $J = 8.0$, 1H); ^{13}C NMR ($DMSO-d_6$) δ 162.0 (s), 156.3 (s), 147.2 (s), 138.9 (s), 128.8 (d), 128.3 (d), 127.9 (s), 125.2 (d), 125.1 (d), 124.2 (s), 122.6 (d), 121.9 (d), 119.8 (d), 117.5 (s), 112.5 (d); EIMS m/z 235 $[M]^+$ (calcd for $C_{15}H_9NO_2$, 235).

11-Chlorobenzofuro[3,2-b]quinoline (38). Compound **38** (64 mg) was synthesized as previously described.^{18c} 1H NMR ($CDCl_3$) δ 8.82 (dd, $J = 8.8$, 1.2, 1H), 8.08 (dd, $J = 8.0$, 1.2, 1H), 7.73 (dd, $J = 8.0$, 1.6, 1H), 7.59 (td, $J = 8.0$, 1.6, 1H), 7.26 (td, $J = 8.0$, 1.6, 1H), 7.11 (td, $J = 8.0$, 1.2, 1H), 6.78 (td, $J = 8.0$, 1.2, 1H), 6.71 (dd, $J = 8.0$, 1.2, 1H); EIMS m/z 255, 253 $[M]^+$, 218 $[M - Cl]^+$, 190 (calcd for $C_{15}H_8NOCl$, 255, 253).

11-Iodobenzofuro[3,2-b]quinoline (39). A mixture of compound **38** (12 mg), iodomethane (0.7 mL), NaOMe (26 mg), and anhydrous MeOH (2 mL) was refluxed for 24 h. Methanol was removed in vacuo, and the residue was partitioned between H_2O and EtOAc. The EtOAc layer was dried, and the resulting solid (14 mg) was collected as **39**. 1H NMR (CD_3OD) δ 8.29 (d, $J = 8.0$, 1H), 8.19 (d, $J = 8.4$, 1H), 8.14 (d, $J = 8.0$, 1H), 7.89 (d, $J = 8.4$, 1H), 7.83 (t, $J = 8.0$, 1H), 7.77 (m, 2H), 7.55 (t, $J = 8.0$, 1H); EIMS: 345 $[M]^+$, 218 $[M - I]^+$, 180 (calcd for $C_{15}H_8NOI$, 345).

Benzofuro[3,2-*b*]quinoline (40). A mixture of compound **38** (30 mg) and 10% Pd/C (60 mg) in 4 mL of alcoholic KOH (1N) under H₂ was left at room temperature for 12 h. The Pd/C was removed by filtration through Celite, and EtOH was removed in vacuo. Acetone (1 mL) and distilled water (1 mL) were added to the residue. The insoluble precipitate (20 mg) was collected and identified as product **40** (78%). ¹H NMR (CDCl₃) δ 8.39 (d, *J* = 8.0), 8.30 (d, *J* = 8.5), 8.16 (s), 7.97 (d, *J* = 8.0), 7.73 (ddd, *J* = 8.0, 8.5, 1.0), 7.6 (m, 3H), 7.46 (ddd, *J* = 8.0, 8.5, 1.0); ¹³C NMR (CDCl₃) δ 159.6 (s), 147.9 (s), 147.5 (s), 146.1 (s), 130.9 (d), 129.3 (d), 128.0 (d), 127.9 (d), 127.4 (s), 126.1 (d), 123.6 (d), 122.9 (s), 122.2 (d), 114.5 (d), 112.2 (d); EIMS *m/z* 219 [M]⁺, 190 (calcd for C₁₅H₉NO, 219).

5-*N*-Methylbenzofuro[3,2-*b*]quinolinium iodide (41). A mixture of compound **40** (16 mg), iodomethane (0.5 mL), NaOMe (20 mg), and anhydrous MeOH (2 mL) was refluxed for 24 h.²¹ Ether was added, and the precipitate was obtained through filtration. The solid was washed with CH₂Cl₂, collected, and identified as compound **41** (12 mg). ¹H NMR (CD₃-OD) δ 9.41 (s, 1H, H-11), 8.80 (dd, *J* = 8.0, 1.2, 1H, H-6), 8.74 (d, *J* = 8.8, 1H, H-4), 8.55 (dd, *J* = 8.4, 1.6, 1H, H-1), 8.30 (td, *J* = 8.4, 1.6, 1H, H-3), 8.11 (td, *J* = 8.4, 1.2, 1H, H-8), 8.03 (m, 2H, H-2 and H-9), 7.81 (td, *J* = 8.4, 1.2, 1H, H-7), 5.10 (s, 3H, 5-*N*-CH₃); ¹³C NMR (CD₃OD) δ 162.3 (s, C-9a), 149.5 (s, C-10a), 144.5 (s, C-5a), 138.9 (s, C-4a), 137.5 (d, C-8), 135.6 (d, C-3), 131.9 (d, C-1), 130.1 (d, C-2), 129.1 (s, C-11a), 127.5 (d, C-6), 127.2 (d, C-11), 126.9 (d, C-7), 119.1 (d, C-4), 117.8 (s, C-5b), 114.8 (d, C-5b), 41.4 (q, 5-*N*-CH₃), assigned by ¹H-¹H COSY and HMBC; FABMS *m/z* 234 [M - I]⁺; HRFABMS *m/z* 234.0914 [M - I]⁺ (calcd for C₁₆H₁₂NO, 234.0919).

Yeast Bioassay. The manipulated yeast (1138, 1140, and 1353) assay was performed on a 9-well agar plate as previously described.^{2c}

Cytotoxicity Assays. Cytotoxicity bioassays were carried out in the M109 cell line at Bristol-Myers Squibb Pharmaceutical Research Institute by standard methods, with the results indicated in Table 1. Compounds **6** and **22** were also tested in a panel of 25 cell lines; both compounds gave similar patterns, with the cell lines OVCAR-3 (IC₅₀ 0.5 μM) and A431 (IC₅₀ 0.34 μM) being the most sensitive and M109 (IC₅₀ 5.6 μM) and MLF (IC₅₀ 4.9 μM) being the least sensitive.

Induction of Cell Cycle Dependent Growth Disturbances. Compounds **6** and **22** were subjected to analysis of their effect on cell cycle dependent growth disturbances. FACS analysis was done after 24 h exposure at increasing IC₅₀ concentrations of these drugs. Results showed a G1 cell cycle arrest and apoptosis in A2780/p53wt cells at 5 × IC₅₀. Higher concentrations showed a dose dependent increase in apoptosis. This effect appears to be p53 dependent since A2780/mutp53 cells showed no arrest in G1 and at 10 × IC₅₀ showed a slow cell cycle traverse with some arrest at G2/M. Apoptosis was present only at 20 × IC₅₀. These characteristics are typical of DNA damaging agents.

Acknowledgment. This work was supported by an International Collaborative Biodiversity Grant, number U01 TW/CA-00313 from the Fogarty Center, NIH, and this support is

gratefully acknowledged. Mass spectra were obtained by Mr. Kim Harich of Virginia Polytechnic Institute and State University and the Midwest Center for Mass Spectroscopy in the Department of Chemistry, University of Nebraska.

References and Notes

- (1) Biodiversity Conservation and Drug Discovery in Suriname. Part 5. For Part 4, see ref 2d.
- (2) (a) Zhou, B.-N.; Baj, N. J.; Glass, T. E.; Malone, S.; Werkhoven, M. C. M.; van Troon, F.; David, M.; Wisse, J.; Bursuker, I.; Neddermann, K.; Kingston, D. G. I. *J. Nat. Prod.*, **1997**, *60*, 1287–1293. (b) Abdel-Kader, M. S.; Wisse, J. H.; Evans, R.; van der Werff, H.; Kingston, D. G. I. *J. Nat. Prod.*, **1997**, *60*, 1294–1297. (c) Abdel-Kader, M. S.; Bahler, B. D.; Malone, S.; Werkhoven, M. C. M.; van Troon, F.; David, M.; Wisse, J. H.; Burkuser, I.; Neddermann, K. M.; Mamber, S. W.; Kingston, D. G. I. *J. Nat. Prod.*, **1998**, *61*, 1202–1208. (d) Yang, S.-W.; Zhou, B.-N.; Wisse, J. H.; Evans, R.; van der Werff, H.; Miller, J. S.; Kingston, D. G. I. *J. Nat. Prod.*, **1998**, *61*, 901–906.
- (3) The tribal healers of Suriname frequently use mixtures of plants in their treatments. For this reason, some collections of combinations of plants were made in order to test whether such combinations had any improved efficacy as compared with single plants.
- (4) Nitiss, J.; Wang, J. C. *Proc. Natl. Acad. Sci. U.S.A.*, **1988**, *85*, 7501–7505.
- (5) Ablordepey, S. Y.; Hufford, C. D.; Borne, R. F.; Dwuma-Badu, D. *Planta Med.*, **1990**, *56*, 416–417.
- (6) Clinquart, E. *Bull. Acad. R. Med. Belg.*, **1929**, *9*, 627–635.
- (7) Delvaux, E. *J. Pharm. Belg.*, **1931**, *13*, 955–959.
- (8) Gunatilaka, A. A. L.; Sotheeswaran, S.; Balasubramaniam, S.; Chandrasekara, A. I.; Sriyani, H. T. B. *Planta Med.*, **1980**, *39*, 66–72.
- (9) Bierer, D. E.; Fort, D. M.; Mendez, C. D.; Luo, J.; Imbach, P. A.; Dubenko, L. G.; Jolad, S. D.; Gerber, R. E.; Litvak, J.; Lu, Q.; Zhang, P.; Reed, M. J.; Waldeck, N.; Bruening, R. C.; Noamesi, B. K.; Hector, R. F.; Carlson, T. J.; King, S. R. *J. Med. Chem.*, **1998**, *41*, 894–901.
- (10) (a) Fichter, F.; Boehringer, R. *Chem. Ber.*, **1906**, *39*, 3932–3942. (b) Fichter, F.; Probst, H. *Chem. Ber.*, **1907**, *40*, 3478–3488. (c) Fichter, F.; Rohner, F. *Chem. Ber.*, **1907**, *40*, 3489–3499.
- (11) (a) Holt, S. J.; Petrow, V. *J. Chem. Soc.*, **1947**, 607–611. (b) Holt, S. J.; Petrow, V. *J. Chem. Soc.*, **1948**, 919–922. (c) Cooper, M. M.; Lovell, J. M.; Joule, J. A. *Tetrahedron Lett.*, **1996**, *37*, 4283–4286.
- (12) Paulo, A.; Gomes, E. T.; Houghton, P. J. *J. Nat. Prod.*, **1995**, *58*, 1485–1491.
- (13) Tackie, A. N.; Boye, G. L.; Sharaf, M. H. M.; Schiff, P. L., Jr.; Crouch, R. C.; Spitzer, T. D.; Johnson, R. L.; Dunn, J.; Minick, D.; Martin, G. E. *J. Nat. Prod.*, **1993**, *56*, 653–670.
- (14) Cimanga, K.; De Bruyne, T.; Pieters, L.; Claeys, M.; Vlietinck, A. *Tetrahedron Lett.*, **1996**, *37*, 1703–1706.
- (15) Poussset, J. L.; Martin, M.-T.; Jossang, A.; Bodo, B. *Phytochemistry*, **1995**, *39*, 735–736.
- (16) Bierer, D. E.; Dubenko, L. G.; Zhang, P.; Lu, Q.; Imbach, P. A.; Garofalo, A. W.; Phuan, P.-W.; Fort, D. M.; Litvak, J.; Gerber, R. E.; Sloan, B.; Luo, J.; Cooper, R.; Reaven, G. M. *J. Med. Chem.*, **1998**, *41*, 2754–2764.
- (17) Bair, K. W.; Tuttle, R. L.; Knick, V. C.; Cory, M.; McKee, D. D. *J. Med. Chem.*, **1990**, *33*, 2385–2393.
- (18) (a) Reid, W.; Berg, A.; Schmidt, G. *Chem. Ber.*, **1952**, *85*, 216–224. (b) Stadlbauer, W.; Schmut, O.; Kappe, T. *Monatsh. Chem.*, **1980**, *111*, 1005–1013. (c) Sunder S.; Peet, N. P. *J. Heterocycl. Chem.*, **1978**, *15*, 1379–1382.
- (19) Ablordepey, S. Y.; Hufford, C. D.; Borne, R. F.; Dwuma-Badu, D. *Planta Med.*, **1990**, *56*, 416–417.
- (20) Spitzer, T. D.; Crouch, R. C.; Martin, G. E.; Sharaf, M. H. M.; Schiff, P. L., Jr.; Tackie, A. N.; Boye, G. L. *J. Heterocycl. Chem.*, **1991**, *28*, 2065–2070.
- (21) Kaslow, C. E.; Moe, H. *J. Org. Chem.*, **1960**, *25*, 1512–1516.

NP990035G